About
Contact & Profiles
Research Areas
- Coronary Interventions and Diagnostics
- Peripheral Artery Disease Management
- Cardiac Valve Diseases and Treatments
- Cerebrovascular and Carotid Artery Diseases
- Cardiac pacing and defibrillation studies
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Imaging and Diagnostics
- Cardiovascular Function and Risk Factors
- Healthcare and Venom Research
- Mechanical Circulatory Support Devices
- Venous Thromboembolism Diagnosis and Management
- Acute Kidney Injury Research
- Economic and Financial Impacts of Cancer
- Chemotherapy-induced cardiotoxicity and mitigation
- Ocular Diseases and Behçet’s Syndrome
- Kawasaki Disease and Coronary Complications
- Cardiac Arrest and Resuscitation
- Advanced Breast Cancer Therapies
- Cardiac Health and Mental Health
- Pharmaceutical Economics and Policy
- Acute Myocardial Infarction Research
- Renal and Vascular Pathologies
- Health Systems, Economic Evaluations, Quality of Life
- Atrial Fibrillation Management and Outcomes
- Retinal and Optic Conditions
The University of Texas MD Anderson Cancer Center
2024-2025
The University of Texas Health Science Center at San Antonio
2024
10.1016/j.jcin.2025.01.401
article
EN
КАРДИОЛОГИЯ УЗБЕКИСТАНА
2025-02-01
10.1016/j.jcin.2025.01.389
article
EN
КАРДИОЛОГИЯ УЗБЕКИСТАНА
2025-02-01
10.1016/j.jcin.2025.01.361
article
EN
КАРДИОЛОГИЯ УЗБЕКИСТАНА
2025-02-01
10.1016/j.jcin.2025.01.374
article
EN
КАРДИОЛОГИЯ УЗБЕКИСТАНА
2025-02-01
10.1016/j.jcin.2025.01.343
article
EN
КАРДИОЛОГИЯ УЗБЕКИСТАНА
2025-02-01
10.1016/j.jcin.2025.01.353
article
EN
КАРДИОЛОГИЯ УЗБЕКИСТАНА
2025-02-01
10.1016/j.jcin.2025.01.287
article
EN
КАРДИОЛОГИЯ УЗБЕКИСТАНА
2025-02-01
10.1016/j.jcin.2025.01.288
article
EN
КАРДИОЛОГИЯ УЗБЕКИСТАНА
2025-02-01
10.1016/j.jcin.2025.01.247
article
EN
КАРДИОЛОГИЯ УЗБЕКИСТАНА
2025-02-01
10.1016/j.jcin.2025.01.222
article
EN
КАРДИОЛОГИЯ УЗБЕКИСТАНА
2025-02-01
10.1016/j.jcin.2025.01.139
article
EN
КАРДИОЛОГИЯ УЗБЕКИСТАНА
2025-02-01
10.1016/j.jcin.2025.01.131
article
EN
КАРДИОЛОГИЯ УЗБЕКИСТАНА
2025-02-01
10.1016/j.jcin.2025.01.109
article
EN
КАРДИОЛОГИЯ УЗБЕКИСТАНА
2025-02-01
10.1016/j.jcin.2025.01.117
article
EN
КАРДИОЛОГИЯ УЗБЕКИСТАНА
2025-02-01
10.1016/j.jcin.2025.01.071
article
EN
КАРДИОЛОГИЯ УЗБЕКИСТАНА
2025-02-01
10.1016/j.jcin.2025.01.054
article
EN
КАРДИОЛОГИЯ УЗБЕКИСТАНА
2025-02-01
10.1016/j.jcin.2025.01.044
article
EN
КАРДИОЛОГИЯ УЗБЕКИСТАНА
2025-02-01
10.1016/j.jcin.2025.01.033
article
EN
КАРДИОЛОГИЯ УЗБЕКИСТАНА
2025-02-01
10.1016/j.jcin.2025.01.042
article
EN
КАРДИОЛОГИЯ УЗБЕКИСТАНА
2025-02-01
10.1016/j.jcin.2025.01.017
article
EN
КАРДИОЛОГИЯ УЗБЕКИСТАНА
2025-02-01
The absence of a Food and Drug Administration-approved percutaneous valve technology for the treatment severe aortic regurgitation (AR) presents challenge high-risk patients. In this report, we describe successful an 84-year-old male patient suffering from symptomatic AR concomitant cardiorenal syndrome with renal failure using 34 mm Evolut R (Medtronic) self-expanding transcatheter replacement. This intervention resulted in resolution AR, syndrome, congestive heart symptoms.
10.15420/usc.2024.19
article
EN
cc-by-nc
US Cardiology Review
2024-11-13
10.25270/jic/24.00352
article
EN
Deleted Journal
2024-01-01
10.1016/j.jval.2022.09.640
article
EN
publisher-specific-oa
Value in Health
2022-12-01
Coming Soon ...